EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Homologous Repair‐Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy

Alica K Beutel iD, Christopher J Halbrook iD, Menar Ekizce iD, Jessica Lindenmayer iD, Elodie Roger iD, Sabrina E Calderon, Thomas Seufferlein iD, Alexander Kleger iD, Johann Gout iD, Lukas Perkhofer iD

United European Gastroenterology Journal · 2025-09 · 13 (7) · 1328-1342

DOI: 10.1002/ueg2.12773 ↗

Kurz gefasst

Fachartikel in der Zeitschrift United European Gastroenterology Journal, online erschienen am 18.08.2025. Verfasst von Alica K Beutel und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Poly(ADP-ribose) Polymerase Inhibitors, Carcinoma, Pancreatic Ductal, DNA Damage. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ulm University and the German Cancer Aid, NCI NIH HHS, Sachbeihilfe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with a high mortality rate. While up to 20% of PDAC patients harbor mutations in genes involved in homologous recombination (HR) repair, only 5% of germline BRCA1/2 mutation carriers have an approved treatment option with the PARP inhibitor (PARPi) olaparib. Characterizing HR‐deficient (HRD) genotypes beyond g BRCA1/2 that are susceptible to PARPi has potential to substantially broaden the eligible patient population, and defining the optimal inhibitor may further optimize treatment strategies to advance personalized medicine in PDAC.

Objective

Our previous preclinical work showed synthetic lethality of a multi‐pronged DNA damage repair interference strategy using the PARPi olaparib, ATR inhibitor VE‐822, and DNA‐PK inhibitor CC‐115 (termed PAD) in ATM deficiency. In the present study, we challenged the role of olaparib in our PAD combination and assessed the regimen's efficacy across various HRD genotypes.

Methods

We assessed a spectrum of DNA damage repair‐interfering drugs to identify the most potent inhibitor in HRD. Using ATM , BRCA1 , BRCA2 and PALB2 ‐defective versus HR‐proficient murine PDAC cells, we systematically investigated the feasibility of expanding an optimized PAD regimen within defined HRD genotypes in vitro and in vivo. The regimen's efficacy was validated in PDAC patient‐derived organoids with and without deleterious class IV/V alterations in HRD genes. Results and Conclusion Here, we demonstrate a remarkable potency of the PARPi talazoparib in HRD PDAC. Substituting olaparib, currently the only approved inhibitor in PDAC, with talazoparib in our PAD regimen enhanced its efficacy while maintaining comparable tolerability in vivo. Importantly, we show that PAD is an effective therapeutic regimen that can be extended to the most prevalent HR‐defective genotypes in PDAC including ATM , BRCA1 , BRCA2 and PALB2 in a preclinical setting. Collectively, these data provide a strong rationale to implement the refined regimen, talazoparib‐based PAD, as a therapeutic concept tailored for HRD PDAC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsPoly(ADP-ribose) Polymerase InhibitorsCarcinoma, Pancreatic DuctalDNA DamageRecombinational DNA RepairAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsPiperazinesPhthalazinesMiceCell Line, TumorXenograft Model Antitumor AssaysAtaxia Telangiectasia Mutated ProteinsBRCA2 ProteinBRCA1 ProteinDNA RepairFanconi Anemia Complementation Group N Protein

Stichwörter der Autor:innen

ATM serine/threonine kinase (ATM)PARP inhibitor (PARPi)breast cancer gene 1/2 (BRCA1/2)homologous recombination deficiency (HRD)pancreatic ductal adenocarcinoma (PDAC)partner and localizer of BRCA2 (PALB2)personalized medicinetalazoparibtargeted therapy

Substanzen

olaparibPiperazinesPhthalazinesPoly(ADP-ribose) Polymerase InhibitorsAtaxia Telangiectasia Mutated ProteinsBRCA2 ProteinBRCA1 ProteinFanconi Anemia Complementation Group N ProteinBRCA1 protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany.
  • Department of Molecular Biology and Biochemistry, University of California Irvine, Irvine, California, USA.
  • Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California, USA.
  • Institute of Molecular Oncology and Stem Cell Biology, Ulm University Hospital, Ulm, Germany.
  • Core Facility Organoids, Ulm University, Ulm, Germany.
  • Division of Interdisciplinary Pancreatology, Department of Internal Medicine I, Ulm University Hospital, Ulm, Germany.

ORCID-Profile: Alica K Beutel, Christopher J Halbrook, Menar Ekizce, Jessica Lindenmayer, Elodie Roger, Thomas Seufferlein, Alexander Kleger, Johann Gout, Lukas Perkhofer

Förderung

  • Ulm University and the German Cancer Aid
  • NCI NIH HHS
  • Sachbeihilfe
  • V Scholar award
  • Sky Foundation Research Grant
  • German Cancer Aid
  • "Bausteinprogramm" of Ulm University
  • Heisenberg-Programm

Zitieren

APA

Beutel, A. K., Halbrook, C. J., Ekizce, M., Lindenmayer, J., Roger, E., Calderon, S. E., Seufferlein, T., Kleger, A., Gout, J., & Perkhofer, L. (2025). Homologous Repair‐Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy. United European Gastroenterology Journal, 13(7), 1328-1342. https://doi.org/10.1002/ueg2.12773

Vancouver

Beutel AK, Halbrook CJ, Ekizce M, Lindenmayer J, Roger E, Calderon SE, et al. Homologous Repair‐Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy. United European Gastroenterology Journal. 2025;13(7):1328-1342. doi:10.1002/ueg2.12773

BibTeX
@article{Beutel2025,
  author = {Beutel, Alica K and Halbrook, Christopher J and Ekizce, Menar and Lindenmayer, Jessica and Roger, Elodie and Calderon, Sabrina E and Seufferlein, Thomas and Kleger, Alexander and Gout, Johann and Perkhofer, Lukas},
  title = {Homologous Repair‐Deficient Pancreatic Cancer: Refined Targeting of DNA Damage Response is an Effective Therapeutic Strategy},
  journal = {United European Gastroenterology Journal},
  year = {2025},
  volume = {13},
  number = {7},
  pages = {1328--1342},
  doi = {10.1002/ueg2.12773}
}
Kostenlos starten →